Target intelligence / Profile preview

Novel transcript, antisense to MYNN (ENSG00000269984)

Target
ENSG00000269984
Molecular classification
Noncoding RNA, Natural antisense transcript (NAT), Long noncoding RNA (lncRNA)
01

Overview

Novel transcript, antisense to MYNN" (ENSG00000269984) is a natural antisense long noncoding RNA transcribed from a region opposite the MYNN gene locus. This class of noncoding RNA is known as a **natural antisense transcript (NAT)**, and such molecules are widespread in the human genome. NATs can regulate the expression of their corresponding sense (protein-coding) gene through several mechanisms: transcriptional interference, chromatin remodeling, transcript stability modulation, and RNA masking[1][2][3]. Although antisense RNAs are increasingly recognized for their roles in gene regulation, the precise biological function and disease relevance of most individual NATs—including this transcript—remain unknown. They are generally not considered direct therapeutic targets, but can potentially affect cellular processes or diseases that involve their sense gene partners. If future research identifies specific regulatory or disease associations for this antisense RNA, these entries may require updating.

02

Mechanism of action

Not applicable/none established

03

Biological functions

Regulation of gene expression (by antisense pairing, chromatin remodeling, or transcriptional interference)Other (potentially unknown, as specific data for this transcript is lacking)
04

Disease associations

Other (no documented direct disease association for this specific antisense RNA, but some antisense RNAs generally affect cell biology and disease pathways through gene regulation)
05

Safety considerations

None reportedBroader off-target effects of modulating antisense RNAs are a theoretical concern in nucleic acid therapies in general.

Beyond the preview

Go deeper on Novel transcript, antisense to MYNN (ENSG00000269984).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel transcript, antisense to MYNN (ENSG00000269984).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call